Daniel W Visscher1, Marlene H Frost2, Lynn C Hartmann2, Ryan D Frank3, Robert A Vierkant3, Ann E McCullough1, Stacey J Winham3, Celine M Vachon4, Karthik Ghosh5, Kathleen R Brandt6, Ann M Farrell7, Yaman Tarabishy8, Tina J Hieken9, Tufia C Haddad2, Ruth A Kraft10, Derek C Radisky11, Amy C Degnim9. 1. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota. 2. Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota. 3. Department of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota. 4. Health Science Research, Mayo Clinic, Rochester, Minnesota. 5. Department of General Internal Medicine, Mayo Clinic, Rochester, Minnesota. 6. Department of Radiology, Mayo Clinic, Rochester, Minnesota. 7. Library, Mayo Clinic, Rochester, Minnesota. 8. Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri. 9. Department of Surgery, Mayo Clinic, Rochester, Minnesota. 10. Research Services, Mayo Clinic, Rochester, Minnesota. 11. Division of Cancer Biology, Mayo Clinic Florida, Jacksonville, Florida.
Abstract
BACKGROUND: Women with benign breast disease (BBD) have an increased risk of developing breast cancer (BC). Nearly 30% of all BCs develop in women with prior BBD. Information regarding features of the expected number of BCs after BBD would enhance individualized surveillance and prevention strategies for these women. In the current study, the authors sought to characterize BCs developing in a large cohort of women with BBD. METHODS: The current study cohort included 13,485 women who underwent breast biopsy for mammographic or palpable concerns between 1967 and 2001. Biopsy slides were reviewed and classified as nonproliferative disease, proliferative disease without atypia, or atypical hyperplasia. BCs were identified by follow-up questionnaires, medical records, and Tumor Registry data. BC tissues were obtained and reviewed. RESULTS: With median follow-up of 15.8 years, 1273 women developed BC. The majority of BCs were invasive (81%), of which 61% were ductal, 13% were mixed ductal/lobular, and 14% were lobular. Approximately two-thirds of the BC cases were intermediate or high grade, and 29% were lymph node positive. Cancer characteristics were similar across the 3 histologic categories of BBD, with a similar frequency of ductal carcinoma in situ, invasive disease, tumor size, time to invasive BC, histologic type of BC, lymph node positivity, and human epidermal growth factor receptor 2 positivity. Women with atypical hyperplasia were found to have a higher frequency of estrogen receptor-positive BC (91%) compared with women with proliferative disease without atypia (80%) or nonproliferative disease (85%) (P = .02). CONCLUSIONS: A substantial percentage of all BCs develop in women with prior BBD. The majority of BCs after BBD are invasive tumors of ductal type, with a substantial number demonstrating lymph node positivity. Of all the BCs in the current study, 84% were estrogen receptor positive. Prevention therapy should be strongly encouraged in higher-risk women with BBD.
BACKGROUND:Women with benign breast disease (BBD) have an increased risk of developing breast cancer (BC). Nearly 30% of all BCs develop in women with prior BBD. Information regarding features of the expected number of BCs after BBD would enhance individualized surveillance and prevention strategies for these women. In the current study, the authors sought to characterize BCs developing in a large cohort of women with BBD. METHODS: The current study cohort included 13,485 women who underwent breast biopsy for mammographic or palpable concerns between 1967 and 2001. Biopsy slides were reviewed and classified as nonproliferative disease, proliferative disease without atypia, or atypical hyperplasia. BCs were identified by follow-up questionnaires, medical records, and Tumor Registry data. BC tissues were obtained and reviewed. RESULTS: With median follow-up of 15.8 years, 1273 women developed BC. The majority of BCs were invasive (81%), of which 61% were ductal, 13% were mixed ductal/lobular, and 14% were lobular. Approximately two-thirds of the BC cases were intermediate or high grade, and 29% were lymph node positive. Cancer characteristics were similar across the 3 histologic categories of BBD, with a similar frequency of ductal carcinoma in situ, invasive disease, tumor size, time to invasive BC, histologic type of BC, lymph node positivity, and humanepidermal growth factor receptor 2 positivity. Women with atypical hyperplasia were found to have a higher frequency of estrogen receptor-positive BC (91%) compared with women with proliferative disease without atypia (80%) or nonproliferative disease (85%) (P = .02). CONCLUSIONS: A substantial percentage of all BCs develop in women with prior BBD. The majority of BCs after BBD are invasive tumors of ductal type, with a substantial number demonstrating lymph node positivity. Of all the BCs in the current study, 84% were estrogen receptor positive. Prevention therapy should be strongly encouraged in higher-risk women with BBD.
Authors: Bernadette K McLaren; Peggy A Schuyler; Melinda E Sanders; Roy A Jensen; Jean F Simpson; William D Dupont; David L Page Journal: Cancer Date: 2006-09-15 Impact factor: 6.860
Authors: Lisa J Herrinton; William E Barlow; Onchee Yu; Ann M Geiger; Joann G Elmore; Mary B Barton; Emily L Harris; Sharon Rolnick; Roy Pardee; Gail Husson; Ana Macedo; Suzanne W Fletcher Journal: J Clin Oncol Date: 2005-03-28 Impact factor: 44.544
Authors: M H Gail; L A Brinton; D P Byar; D K Corle; S B Green; C Schairer; J J Mulvihill Journal: J Natl Cancer Inst Date: 1989-12-20 Impact factor: 13.506
Authors: Lynn C Hartmann; Thomas A Sellers; Marlene H Frost; Wilma L Lingle; Amy C Degnim; Karthik Ghosh; Robert A Vierkant; Shaun D Maloney; V Shane Pankratz; David W Hillman; Vera J Suman; Jo Johnson; Cassann Blake; Thea Tlsty; Celine M Vachon; L Joseph Melton; Daniel W Visscher Journal: N Engl J Med Date: 2005-07-21 Impact factor: 91.245
Authors: Karla Kerlikowske; Charlotte C Gard; Jeffrey A Tice; Elad Ziv; Steven R Cummings; Diana L Miglioretti Journal: J Natl Cancer Inst Date: 2016-12-31 Impact factor: 13.506
Authors: S David Nathanson; David Krag; Henry M Kuerer; Lisa A Newman; Markus Brown; Dontscho Kerjaschki; Ethel R Pereira; Timothy P Padera Journal: Clin Exp Metastasis Date: 2018-05-23 Impact factor: 5.150
Authors: Zexian Zeng; Andy Vo; Xiaoyu Li; Ali Shidfar; Paulette Saldana; Luis Blanco; Xiaoling Xuei; Yuan Luo; Seema A Khan; Susan E Clare Journal: NPJ Breast Cancer Date: 2020-06-12
Authors: Ellen L Nutter; Julia E Weiss; Jonathan D Marotti; Richard J Barth; M Scottie Eliassen; Martha E Goodrich; Curtis L Petersen; Tracy Onega Journal: Cancer Date: 2017-12-20 Impact factor: 6.860
Authors: Nur Zeinomar; Kelly-Anne Phillips; Mary B Daly; Roger L Milne; Gillian S Dite; Robert J MacInnis; Yuyan Liao; Rebecca D Kehm; Julia A Knight; Melissa C Southey; Wendy K Chung; Graham G Giles; Sue-Anne McLachlan; Michael L Friedlander; Prue C Weideman; Gord Glendon; Stephanie Nesci; Irene L Andrulis; Saundra S Buys; Esther M John; John L Hopper; Mary Beth Terry Journal: Int J Cancer Date: 2019-02-20 Impact factor: 7.396
Authors: Lisa A Newman; Azadeh Stark; Dhanajay Chitale; Margaret Pepe; Gary Longton; Maria J Worsham; S David Nathanson; Patricia Miller; Jessica M Bensenhaver; Erica Proctor; Monique Swain; Christos Patriotis; Paul F Engstrom Journal: JAMA Oncol Date: 2017-08-01 Impact factor: 31.777
Authors: Christiane K Kuhl; Annika Keulers; Kevin Strobel; Hannah Schneider; Nadine Gaisa; Simone Schrading Journal: Breast Cancer Res Date: 2018-02-09 Impact factor: 6.466